Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Armata Pharmaceuticals, Inc. (ARMP)

ASE · Biotechnology

$4.73-0.42 (-8.16%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$173.6M
P/E (TTM)
EPS
$-7.15
Div Yield
52W Range
$2.35–$16.34
Beta
1.27

Company overview

Next earnings: 2026-08-11(14d)

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Peers in Biotechnology

All in industry →

Recent press releases

Armata Pharmaceuticals, Inc. has not issued a press release in this window.

SEC filings

All filings →

Armata Pharmaceuticals, Inc. has not filed an SEC document in this window.

Armata Pharmaceuticals, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
357,649 sh+20.4%
139,860 sh● NEW
109,888 sh+5.1%
72,764 sh+172.9%
100,000 sh0.0%
68,496 sh+65.9%
45,163 sh● NEW
50,800 sh+26.1%

People at Armata Pharmaceuticals, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$6.5M
06/25
NI -$16.3M
09/25
NI -$26.7M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.74
Prior: $-0.45
Revenue sparkline